Mechanism 40 After exposure improves
Persistent regulatory memory
A persistent gene-regulatory state may sustain nerve injury after the initiating diabetic exposure improves.
- Base belief in the full proposition
- 3.3%
- Skeptical–favorable sensitivity
- 0.09–30.6%
Calculated from this report’s conditional judgments. These are subjective causal probabilities; the range shows scenario sensitivity. How to read the numbers.
Complete MarkdownStructured JSON
Claims & probabilities
Each conditional probability assumes every preceding claim is true in the same group and mechanism. Cumulative belief is their running product. Questions summarize the claims; the exact wording gives the full criteria.
See the full causal proposition for this report’s population, thresholds, and definitions.
| Claim | Question | Necessary proposition | Conditional | Cumulative | Sensitivity |
|---|---|---|---|---|---|
| R1 | Does diabetic exposure create a persistent gene-regulatory state in peripheral neurons or supporting cells? | Diabetic exposure creates a persistent regulatory state in relevant peripheral cells. | 65% | 65% | 35–85% |
| R2 | Does the gene-regulatory state persist independently of current exposure and changes in cell composition? | The state persists independently of current exposure and cell-composition changes. | 50% | 32.5% | 25–80% |
| R3 | Does the persistent state sustain a harmful biological activity, beyond recording exposure history or supporting adaptation? | It sustains a harmful effector rather than marking history or supporting adaptation. | 45% | 14.6% | 20–75% |
| R4 | Does harmful activity sustained by persistent gene regulation cause new peptidergic structural loss after glycemia improves? | The effector causes new peptidergic structural loss after glycemia improves. | 45% | 6.6% | 20–75% |
| R5 | Would removing the persistent regulatory state avert at least 20% of five-year terminal loss in a subgroup accounting for at least 10% of neuropathy cases after glycemic improvement? | Removing the persistent state would materially reduce that loss. | 50% | 3.3% | 25–80% |
Full causal proposition
Past diabetic exposure installs a persistent gene-regulatory state in peripheral neurons or supporting cells that continues to drive axon injury after current glycemia improves.
Scope: Exception: diabetes after a sustained improvement in glycemia, with a five-year injury/progression endpoint. The subgroup threshold refers to neuropathy cases in this post-improvement population. This is persistence of a harmful mediator, not the mere clinical fact that earlier control has lasting benefits.
Causal role: persistent amplification or failed recovery. Unless the scope specifies an exception, materiality means at least 20% less five-year net terminal loss in an identifiable subgroup representing at least 10% of incident DPN cases in the stated population. The target remains human peptidergic C-fibers when a study measures a broader endpoint.
Evidence & details
The report’s reasoning, evidence, resolution criteria, and qualifications follow below.
Source assessment
Base judgment: 3.3%; skeptical–optimistic sensitivity: 0.1%–30.6%. Subjective probabilities of the causal proposition below, not effect sizes. Decimal places only show arithmetic. Reviewed 13 September 2026. Probability method · Collection index.
Reasoning from the biological requirements
Clinical metabolic memory can arise from already lost axons, glycated matrix or accumulated exposure without any persistent epigenetic program. This hypothesis additionally needs a durable regulatory state that remains after the initiating exposure is reduced, produces a harmful effector, and continues causing new loss. A stable methylation difference can be a record of exposure rather than its causal carrier. Reversing a gene mark must change injury through that state, not through unrelated drug effects.
Probabilities of the necessary claims
Conditional prices are skeptical / base / optimistic. Each price after the first assumes all earlier requirements are true. Their order is an order for assessing joint belief, not necessarily a linear biological pathway. The cumulative column uses the base scenario. Temporal order, connected compartments and the causal prevention comparison are included in these requirements, without extra generic multipliers.
See the claims and probabilities table above.
- R1
Human blood epigenetics support exposure memory, not target-cell causation.
- R2
Cross-sectional methylation cannot establish persistence within the same cells.
- R3
The relevant neuronal/glial effector has not been isolated.
- R4
Legacy damage and reduced reserve are strong alternative explanations.
- R5
Selective human mediation and population magnitude remain unknown.
Evidence that moves the judgment
-
Selected DCCT/EDIC blood monocytes/lymphocytes showed histone-modification associations with glycemic history and complications. This supports human exposure-related epigenetic differences, but is not a peripheral-neuron perturbation or proof of a neuropathy mediator. Miao et al., 2014.
-
The repository's public-evidence search did not identify a nerve structural contrast that cleanly separated a persistent glycation/GLO1 mechanism from ongoing exposure and acute rescue. Its GLO1 result demonstrated buffered acute detoxification, not persistence after washout or glucose normalization. Prior correction (background note outside this collection).
Why these odds and how uncertain they are
The broad fact of lasting consequences of diabetes is credible, but epigenetic mediation is a much narrower proposition. The price is low because exposure history, cell composition and irreversible prior damage explain many of the same observations. A compelling molecular mark needs a damaging downstream function and ongoing new injury, not just longitudinal stability.
The skeptical scenario treats marks as records and clinical persistence as legacy damage. The optimistic scenario assumes a reversible harmful state in a definable cell population. Existing human blood evidence offers little precision about which peripheral neuron/glial program, if any, carries the effect.
Conditional inputs: base [65, 50, 45, 45, 50]%; skeptical [35, 25, 20, 20, 25]%; optimistic [85, 80, 75, 75, 80]%. Products give the headline prices. The span measures sensitivity to these interpretations; it is not a statistical confidence interval.
Numerical update example: Public evidence linking a persistent regulatory state to a specific harmful effector after exposure normalization would strengthen requirement 3; a stable mark with no functional effect would weaken it. Changing only requirement 3 from 45% to 80% raises the whole price to 5.9%; reducing it to 10% lowers the price to 0.7%. These are hypothetical evidence updates. Even resolving that one requirement with certainty would leave a complete price of 7.3% if the others stayed unchanged.
Overlap and boundary
Distinct from persistent matrix glycation, senescence and current inflammation. The metabolic-memory topic (background note outside this collection) records related negative analyses; missing identification is not biological disproof.
How to cite this
Edelman, Brice, and Jeffrey Skolnick (2026). “Persistent regulatory memory.” Diabetic Peripheral Neuropathy Mechanism Explorer. Snapshot 14 September 2026. Page permalink.
Include your access date when citing this evolving resource. BibTeX for the collection. For a study’s findings, also cite the original paper linked in the report.